<DOC>
	<DOCNO>NCT02201953</DOCNO>
	<brief_summary>The primary objective study compare efficacy treatment sofosbuvir/velpatasvir ( SOF/VEL ) fixed-dose combination ( FDC ) 12 week sofosbuvir ( SOF ) + ribavirin ( RBV ) 24 week evaluate safety tolerability treatment regimen participant chronic genotype 3 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Comparison Sofosbuvir/Velpatasvir Fixed Dose Combination 12 Weeks With Sofosbuvir Ribavirin 24 Weeks Adults With Chronic Genotype 3 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL HCV genotype 3 Chronic HCV infection ( ≥ 6 month ) Females childbearing potential must negative serum pregnancy test Males females childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Current prior history clinicallysignificant illness ( HCV ) may interfere subject treatment , assessment compliance protocol Screening ECG clinically significant abnormality Laboratory result outside acceptable range Screening Pregnant nursing female male pregnant female partner Chronic liver disease nonHCV etiology ( e.g. , hemochromatosis , Wilson 's disease , alfa1 antitrypsin deficiency , cholangitis ) Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Sofosbuvir</keyword>
	<keyword>Velpatasvir</keyword>
	<keyword>SOF/VEL</keyword>
	<keyword>GS-5816</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Genotype 3</keyword>
</DOC>